Detection of Colorectal Cancer and Advanced Adenoma by Liquid Biopsy (Decalib Study): The DdPCR Challenge

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2020 Jun 11

PMID 32517177

Citations 14

Authors

Audelaure Junca

Gaelle Tachon

Camille Evrard

Claire Villalva

Eric Frouin

Lucie Karayan-Tapon

David Tougeron

Affiliations

Soon will be listed here.

Abstract

Background: In most countries, participation in colorectal cancer (CRC) screening programs with the immunological fecal occult blood test (iFOBT) is low. Mutations of RAS and BRAF occur early in colorectal carcinogenesis and "liquid biopsy" allows detection of mutated circulating tumor DNA (ctDNA). This prospective study aims to evaluate the performance of RAS and BRAF-mutated ctDNA in detecting CRC and advanced adenomas (AA).

Methods: One hundred and thirty patients who underwent colonoscopy for suspicion of colorectal lesion were included and divided into four groups: 20 CRC, 39 AA, 31 non-advanced adenoma and/or hyperplastic polyp(s) (NAA) and 40 with no lesion. Mutated ctDNA was analyzed by droplet digital PCR.

Results: ctDNA was detected in 45.0% of CRC, in 2.6% of AA and none of the NAA and "no-lesion" groups. All patients with stage II to IV mutated CRC had detectable ctDNA ( = 8/8). Among the mutated AA, only one patient had detectable ctDNA (4.3%), maybe due to limited technical sensitivity or to a low rate of ctDNA or even the absence ctDNA in plasma. Specificity and sensitivity of KRAS- and BRAF-mutated ctDNA for the detection of all CRC and AA were 100% and 16.9%, respectively.

Conclusions: ctDNA had high sensitivity in detection of advanced mutated CRC but was unable to sensitively detect AA. ctDNA analysis was easy to perform and readily accepted by the population but requires combination with other circulating biomarkers before replacing iFOBT.

Citing Articles

The tissue and circulating cell-free DNA-derived genetic landscape of premalignant colorectal lesions and its application for early diagnosis of colorectal cancer.

Chen Q, Xu Y, Kang S, Lin W, Luo L, Yang L MedComm (2020). 2024; 5(12):e70011.

PMID: 39554798 PMC: 11564342. DOI: 10.1002/mco2.70011.

Decoding the Dynamics of Circulating Tumor DNA in Liquid Biopsies.

Turabi K, Klute K, Radhakrishnan P Cancers (Basel). 2024; 16(13).

PMID: 39001494 PMC: 11240538. DOI: 10.3390/cancers16132432.

Ultrasensitive plasma-based monitoring of tumor burden using machine-learning-guided signal enrichment.

Widman A, Shah M, Frydendahl A, Halmos D, Khamnei C, Ogaard N Nat Med. 2024; 30(6):1655-1666.

PMID: 38877116 PMC: 7616143. DOI: 10.1038/s41591-024-03040-4.

Early screening of colorectal cancer using feature engineering with artificial intelligence-enhanced analysis of nanoscale chromatin modifications.

Chang A, Prabhala S, Daneshkhah A, Lin J, Subramanian H, Roy H Sci Rep. 2024; 14(1):7808.

PMID: 38565871 PMC: 10987630. DOI: 10.1038/s41598-024-58016-8.

Early screening of colorectal cancer using feature engineering with artificial intelligence-enhanced analysis of nanoscale chromatin modifications.

Chang A, Prabhala S, Daneshkhah A, Lin J, Subramanian H, Roy H Res Sq. 2023; .

PMID: 37961494 PMC: 10635400. DOI: 10.21203/rs.3.rs-3500134/v1.

References

Piton N, Lonchamp E, Nowak F, Sabourin J . Real-Life Distribution of KRAS and NRAS Mutations in Metastatic Colorectal Carcinoma from French Routine Genotyping. Cancer Epidemiol Biomarkers Prev. 2015; 24(9):1416-8. DOI: 10.1158/1055-9965.EPI-15-0059. View

Vitellius C, Laly M, Banaszuk A, Deherce I, Cornet N, Bertrais S . Contribution of the OC Sensor immunoassay in comparison to the Hemoccult II guaiac-test in organized colorectal cancer screening. Eur J Epidemiol. 2018; 34(2):163-172. DOI: 10.1007/s10654-018-0471-z. View

Navarro M, Nicolas A, Ferrandez A, Lanas A . Colorectal cancer population screening programs worldwide in 2016: An update. World J Gastroenterol. 2017; 23(20):3632-3642. PMC: 5449420. DOI: 10.3748/wjg.v23.i20.3632. View

Lecomte T, Ceze N, Dorval E, Laurent-Puig P . Circulating free tumor DNA and colorectal cancer. Gastroenterol Clin Biol. 2010; 34(12):662-81. DOI: 10.1016/j.gcb.2009.04.015. View

Yang H, Mitchell J, Sepulveda J, Sepulveda A . Molecular and histologic considerations in the assessment of serrated polyps. Arch Pathol Lab Med. 2015; 139(6):730-41. DOI: 10.5858/arpa.2014-0424-RA. View

Vaughn C, Zobell S, Furtado L, Baker C, Samowitz W . Frequency of KRAS, BRAF, and NRAS mutations in colorectal cancer. Genes Chromosomes Cancer. 2011; 50(5):307-12. DOI: 10.1002/gcc.20854. View

Lilleberg S, Durocher J, Sanders C, Walters K, Culver K . High sensitivity scanning of colorectal tumors and matched plasma DNA for mutations in APC, TP53, K-RAS, and BRAF genes with a novel DHPLC fluorescence detection platform. Ann N Y Acad Sci. 2004; 1022:250-6. DOI: 10.1196/annals.1318.039. View

Danese E, Minicozzi A, Benati M, Montagnana M, Paviati E, Salvagno G . Comparison of genetic and epigenetic alterations of primary tumors and matched plasma samples in patients with colorectal cancer. PLoS One. 2015; 10(5):e0126417. PMC: 4422441. DOI: 10.1371/journal.pone.0126417. View

Kumar S, Guleria R, Singh V, Bharti A, Mohan A, Das B . Efficacy of circulating plasma DNA as a diagnostic tool for advanced non-small cell lung cancer and its predictive utility for survival and response to chemotherapy. Lung Cancer. 2010; 70(2):211-7. DOI: 10.1016/j.lungcan.2010.01.021. View

10.

Pekin D, Skhiri Y, Baret J, Le Corre D, Mazutis L, Salem C . Quantitative and sensitive detection of rare mutations using droplet-based microfluidics. Lab Chip. 2011; 11(13):2156-66. DOI: 10.1039/c1lc20128j. View

11.

Kopreski M, Benko F, Borys D, Khan A, McGarrity T, Gocke C . Somatic mutation screening: identification of individuals harboring K-ras mutations with the use of plasma DNA. J Natl Cancer Inst. 2000; 92(11):918-23. DOI: 10.1093/jnci/92.11.918. View

12.

Diehl F, Li M, Dressman D, He Y, Shen D, Szabo S . Detection and quantification of mutations in the plasma of patients with colorectal tumors. Proc Natl Acad Sci U S A. 2005; 102(45):16368-73. PMC: 1283450. DOI: 10.1073/pnas.0507904102. View

13.

Lecomte T, Berger A, Zinzindohoue F, Micard S, Landi B, Blons H . Detection of free-circulating tumor-associated DNA in plasma of colorectal cancer patients and its association with prognosis. Int J Cancer. 2002; 100(5):542-8. DOI: 10.1002/ijc.10526. View

14.

Mas L, Bachet J, Taly V, Bouche O, Taieb J, Cohen R . Mutation Status in Circulating Tumor DNA from Patients with Metastatic Colorectal Cancer: Extended Mutation Analysis from the AGEO RASANC Study. Cancers (Basel). 2019; 11(7). PMC: 6679157. DOI: 10.3390/cancers11070998. View

15.

Youden W . Index for rating diagnostic tests. Cancer. 1950; 3(1):32-5. DOI: 10.1002/1097-0142(1950)3:1<32::aid-cncr2820030106>3.0.co;2-3. View

16.

Frattini M, Gallino G, Signoroni S, Balestra D, Lusa L, Battaglia L . Quantitative and qualitative characterization of plasma DNA identifies primary and recurrent colorectal cancer. Cancer Lett. 2008; 263(2):170-81. DOI: 10.1016/j.canlet.2008.03.021. View

17.

Park D, Ryu S, Kim Y, Lee S, Lee C, Eun C . Comparison of guaiac-based and quantitative immunochemical fecal occult blood testing in a population at average risk undergoing colorectal cancer screening. Am J Gastroenterol. 2010; 105(9):2017-25. DOI: 10.1038/ajg.2010.179. View

18.

Van Dam L, Korfage I, Kuipers E, Hol L, van Roon A, Reijerink J . What influences the decision to participate in colorectal cancer screening with faecal occult blood testing and sigmoidoscopy?. Eur J Cancer. 2013; 49(10):2321-30. DOI: 10.1016/j.ejca.2013.03.007. View

19.

Jass J, Baker K, Zlobec I, Higuchi T, Barker M, Buchanan D . Advanced colorectal polyps with the molecular and morphological features of serrated polyps and adenomas: concept of a 'fusion' pathway to colorectal cancer. Histopathology. 2006; 49(2):121-31. PMC: 1619718. DOI: 10.1111/j.1365-2559.2006.02466.x. View

20.

Perrone F, Lampis A, Bertan C, Verderio P, Ciniselli C, Pizzamiglio S . Circulating free DNA in a screening program for early colorectal cancer detection. Tumori. 2014; 100(2):115-21. DOI: 10.1177/030089161410000201. View